001451521 000__ 05709cam\a2200577\i\4500
001451521 001__ 1451521
001451521 003__ OCoLC
001451521 005__ 20230310004704.0
001451521 006__ m\\\\\o\\d\\\\\\\\
001451521 007__ cr\cn\nnnunnun
001451521 008__ 221129s2022\\\\sz\\\\\\ob\\\\001\0\eng\d
001451521 019__ $$a1351447340$$a1351751765
001451521 020__ $$a9783031113635$$q(electronic bk.)
001451521 020__ $$a3031113632$$q(electronic bk.)
001451521 020__ $$z9783031113628
001451521 020__ $$z3031113624
001451521 0247_ $$a10.1007/978-3-031-11363-5$$2doi
001451521 035__ $$aSP(OCoLC)1352092387
001451521 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dEBLCP$$dGW5XE$$dYDX$$dOCLCF$$dUKAHL$$dOCLCQ
001451521 049__ $$aISEA
001451521 050_4 $$aRC111
001451521 08204 $$a616.9$$223/eng/20221130
001451521 24500 $$aInfectious complications in biologic and targeted therapies /$$cCarlos Cervera, Jose Maria Aguado, editors.
001451521 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2022]
001451521 300__ $$a1 online resource.
001451521 336__ $$atext$$btxt$$2rdacontent
001451521 337__ $$acomputer$$bc$$2rdamedia
001451521 338__ $$aonline resource$$bcr$$2rdacarrier
001451521 504__ $$aIncludes bibliographical references and index.
001451521 5050_ $$aIntro -- Preface -- Contents -- Part I: Overview of the Epidemiology, Risk and Prevention of Infections -- 1: Overview of the Risk of Infection Associated with Biologic and Target Therapies -- Overview of Targeted and Biological Therapies -- Monoclonal Antibodies and Related Agents -- Small-Molecule Enzyme Inhibitors -- Assessment of the Risk of Infection -- References -- 2: Timeline and Infectious Disease Evaluation of Candidates to New Therapies -- Introduction -- Timeline of Infectious Complications in Patients on Biologic and Targeted Drugs
001451521 5058_ $$aEvaluation and Prevention of Infectious Complications in Patients on Biologic and Targeted Treatment -- Conclusion -- References -- 3: Safety and Efficacy of Vaccines in Patients on Targeted and Biologic Therapies -- Summary Table -- Evidence Summary by Medication Class -- TNF-Alpha Inhibitors and Abatacept -- Hepatitis B (HBV) Vaccine -- Pneumococcal Vaccine -- Influenza Vaccine -- Live Vaccines -- IL-1 Inhibitors -- IL-6 -- HBV Vaccine -- Pneumococcal Vaccine -- Influenza -- Tetanus -- Live Vaccines -- IL-12/23 -- IL-17 -- Eculizumab -- VEGF Inhibitors (Bevacizumab, Aflibercept)
001451521 5058_ $$aVEGF-R Inhibitors (Sorafenib, Sunitinib, Axitinib, Pazopanib, Regorafenib, Vandetanib, Cabozantinib, Ramucirumab) -- ErbB2/HER2 Inhibitors (Trastuzumab, Pertuzumab) -- ErbB Receptor Tyrosine Kinases (Erlotinib, Gefitinib, Afatinib, Osimertinib, Lapatinib, Neratinib) -- BCR-ABL Tyrosine Kinase Inhibitors (Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib) -- Burton Tyrosine Kinase Inhibitors (Ibrutinib, Acalabrutinib) -- PI3K Inhibitors Idelalisib, Buparlisib, Rigosertib, Duvelisib -- Janus Kinase Inhibitors (Ruxolitinib, Tofacitinib, Baricitinib) -- Pneumococcal Vaccine -- Influenza -- Tetanus
001451521 5058_ $$aLive Zoster Vaccine -- mTOR Inhibitors (Everolimus, Temsirolimus) -- Anti-CD20 (Rituximab, 90Y-Ibritumomab Tiuxetan, Ofatumumab, Ocrelizumab, Veltuzumab, 131I-Tositumomab, Obinutuzumab, Ocaratuzumab, Ublituximab) -- Pneumococcal Vaccine -- Influenza -- Hepatitis B Vaccine -- Tetanus -- Varicella -- Alemtuzumab -- Anti CD-38 (Daratumumab, Isatuxumab) -- CTLA-4 Inhibitors (Ipilimumab, Tremelimumab) -- PD-1 and PD-1 Ligand Inhibitors (Nivolumab, Pembrolizumab, Atezolizumab) -- Influenza Vaccine -- Recombinant Zoster Vaccine -- LFA-3 Inhibitor (Alefacept)
001451521 5058_ $$aAlpha 4-Integrin and LFA-1 Inhibitors (Natalizumab, Vedolizumab, Efalizumab) -- Influenza Vaccine -- Other Vaccines -- Live Vaccines -- Sphingosine 1-Phosphate Receptor Inhibitor (Fingolimod, Siponimod) -- Proteosome Inhibitors (Bortezomib, Carfilzomib, Ixazomib) -- References -- 4: Travel and Risk of Infections -- Introduction -- Infectious Diseases and Risks Factors for Travelers -- Modes of Transmission of Infections -- Risks Factors for Travelers -- Common Infectious Diseases in Travelers -- Gastrointestinal Infections -- Respiratory Infections -- Vector-Borne Infections -- Skin Infections
001451521 506__ $$aAccess limited to authorized users.
001451521 520__ $$aThis book aims to approach the epidemiology, diagnosis and management of infectious complications related to the use of biologic and targeted therapies. The first part is a general overview on the epidemiology and prevention of infections with the use of these agents. Timelines, pre-treatment evaluation, use of vaccines and travel counseling. In the second part, we will analyze the specific risk of infections associated with the use of the most important agents. The third part approach the problem on a syndromic point of view. For example, how to evaluate pulmonary infiltrates in a patient receiving biologic agents. This part III includes the most difficult and conflicting syndromes that clinicians may face when evaluating these patients. This book is intended not only for infectious diseases specialists, but also for different medical specialties prescribing biologic and targeted therapies.
001451521 588__ $$aOnline resource; title from PDF title page (EBSCO, viewed November 30, 2022).
001451521 650_0 $$aInfection$$xPrevention.
001451521 650_0 $$aInfection$$xTreatment.
001451521 650_0 $$aTherapeutics$$xComplications.
001451521 650_0 $$aDrug targeting.
001451521 655_0 $$aElectronic books.
001451521 7001_ $$aCervera, Carlos,$$eeditor.
001451521 7001_ $$aAguado, Jose Maria,$$eeditor.
001451521 77608 $$iPrint version: $$z3031113624$$z9783031113628$$w(OCoLC)1330405632
001451521 852__ $$bebk
001451521 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-031-11363-5$$zOnline Access$$91397441.1
001451521 909CO $$ooai:library.usi.edu:1451521$$pGLOBAL_SET
001451521 980__ $$aBIB
001451521 980__ $$aEBOOK
001451521 982__ $$aEbook
001451521 983__ $$aOnline
001451521 994__ $$a92$$bISE